Difference between revisions of "Main Page"
Line 33: | Line 33: | ||
*[[Media:Guidance Standards for CTs.pdf|Guidance Standards for CTs]] | *[[Media:Guidance Standards for CTs.pdf|Guidance Standards for CTs]] | ||
*[[Media:Guidance biomarker qualification Aug 2011.pdf|Guidance biomarker qualification Aug 2011]] | *[[Media:Guidance biomarker qualification Aug 2011.pdf|Guidance biomarker qualification Aug 2011]] | ||
+ | |||
*[[Media:HHSN268201000050C QIBA Annual Report 30SEP2011.pdf|HHSN268201000050C QIBA (NIBIB) Annual Report]] ''September 2011'' | *[[Media:HHSN268201000050C QIBA Annual Report 30SEP2011.pdf|HHSN268201000050C QIBA (NIBIB) Annual Report]] ''September 2011'' | ||
*[[Media:HHSN268201000050C QIBA SemiAnnual Progress Report MARCH2011.pdf|HHSN268201000050C QIBA (NIBIB) SemiAnnual Progress Report]] ''March 2011'' | *[[Media:HHSN268201000050C QIBA SemiAnnual Progress Report MARCH2011.pdf|HHSN268201000050C QIBA (NIBIB) SemiAnnual Progress Report]] ''March 2011'' | ||
+ | |||
+ | *[[Media:Guidance Standards for CTs.pdf|Guidance Standards for CTs]] | ||
+ | *[[Media:Guidance biomarker qualification Aug 2011.pdf|Guidance biomarker qualification Aug 2011]] | ||
+ | |||
*[[Media:QIBA Round-1 Projects Overview.pdf|QIBA Round-1 Funded Projects Overview]] | *[[Media:QIBA Round-1 Projects Overview.pdf|QIBA Round-1 Funded Projects Overview]] | ||
− | |||
*[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]] | *[[Media:Why_QIBA_CT_specifics.pdf|"Why QIBA?" - Specifics associated with CT device and software manufacturers.]] | ||
*[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]] | *[[Media:Why_QIBA_PET-CT_specifics.pdf|"Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.]] | ||
*[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]] | *[[Media:Why_QIBA_MR_specifics.pdf|"Why QIBA?" - Specifics associated with MR device and software manufacturers.]] | ||
*[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]] | *[[Media:HHSN268201000050C_QIBA_Proposed_Workplan_11-22-2010.doc|QIBA Work Plan (2010.11.22)]] | ||
+ | |||
*[[QIBA posters from RSNA 2011 Annual Meeting]] | *[[QIBA posters from RSNA 2011 Annual Meeting]] | ||
*[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]] | *[[QIBA and UPICT posters from RSNA 2010 Annual Meeting]] | ||
*[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]] | *[[QIBA and UPICT posters from RSNA 2009 Annual Meeting]] | ||
+ | *[[Media:FREEMAN_FINAL_PROOF.pdf|QIBA posters from RSNA 2008 Annual Meeting]] | ||
+ | |||
*[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]] | *[[Media:EU.2009.08.04 Guideline on Clinical evaluation of diagnostic agents.pdf|EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)]] | ||
*[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]] | *[[Media:EU.2009.08.04 Appendix 1 to the guideline.pdf|EMEA Guideline - Appendix 1 (2009.08.04)]] | ||
*[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]] | *[[Media:Oncology section.ppt|Oncology section from 2009 Imaging Biomarkers Roundtable]] | ||
− | |||
==Ad Hoc Committees== | ==Ad Hoc Committees== |
Revision as of 16:47, 3 November 2011
This Wiki is for collaborative creation of QIBA materials and ongoing activities.
Quantitative Imaging Biomarkers Alliance (QIBA)
QIBA Mission: Improve the value and practicality of quantitative biomarkers by reducing variability across devices, patients and time.
QIBA is an initiative to advance quantitative imaging and the use of imaging biomarkers in clinical trials and clinical practice by engaging researchers, healthcare professionals and industry . This involves:
- collaborating to identify needs, barriers, and solutions to develop and test consistent, reliable, valid, and achievable quantitative imaging results across imaging platforms, clinical sites, and time.
- accelerating the development and adoption of hardware and software standards needed to achieve accurate and reproducible quantitative results from imaging methods.
QIBA develops Profile specifications and coordinates the necessary research and qualification groundwork.
QIBA Committees
QIBA currently has five active technical committees:
Public Comment Documents
Documents
- HHSN268201000050C QIBA (NIBIB) Annual Report September 2011
- HHSN268201000050C QIBA (NIBIB) SemiAnnual Progress Report March 2011
- QIBA Round-1 Funded Projects Overview
- "Why QIBA?" - Specifics associated with CT device and software manufacturers.
- "Why QIBA?" - Specifics associated with PET-CT device and software manufacturers.
- "Why QIBA?" - Specifics associated with MR device and software manufacturers.
- QIBA Work Plan (2010.11.22)
- QIBA posters from RSNA 2011 Annual Meeting
- QIBA and UPICT posters from RSNA 2010 Annual Meeting
- QIBA and UPICT posters from RSNA 2009 Annual Meeting
- QIBA posters from RSNA 2008 Annual Meeting
- EMEA Guideline on Clinical Evaluation of Diagnostic Agents (2009.08.04)
- EMEA Guideline - Appendix 1 (2009.08.04)
- Oncology section from 2009 Imaging Biomarkers Roundtable
Ad Hoc Committees
Quantitative Imaging/Imaging Biomarkers and QIBA Meetings and Activities
- QI/IB Special Interest Session-
Imaging Biomarkers for Clinical Care and Research Monday, November 29, 2010 Presentations
- QIBA Annual Meeting Presentations
May 24-25, 2011 Renaissance Arlington Capital View, Arlington VA Presentations
NEW: "How To" help pages
<This Wiki is a Work In Progress: read Help, create an account, contribute>